AXSM

Axsome Therapeutics Inc

AXSM.US axsome.com
220.75
+9.64 (+4.56%)
USD · NASDAQ
52-week range
112.90
260.19
Trading at 73% of the 52-week range
Market Cap
11.56B
P/E Ratio
0.00
Forward P/E
35.09
Book Value
1.59
Div. Yield
N/A
% Institutions
74.62%
% Insiders
15.08%

1 Year

+79.5%

3 Year

+168.5%

10 Year

+2,907.5%
Description

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.

Company Information

Company Name
Axsome Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US05464T1043
CIK: 0001579428
CUSIP: 05464T104
Currency: USD
Full Time Employees: 1,346
Phone: 212 332 3241
Website: axsome.com
Fiscal Year End: December
IPO Date: Nov 19, 2015
Description:

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.

Address:

One World Trade Center, New York, NY, United States, 10007

People

Directors & Officers

Name Title Year Born
Dr. Herriot Tabuteau M.D. Founder, Chairman, CEO & President 1968
Mr. Nick Pizzie CPA, M.B.A. Chief Financial Officer 1975
Mr. Mark L. Jacobson M.A. Chief Operating Officer 1983
Mr. Hunter Murdock Esq. General Counsel & Secretary 1980
Mr. Ari Maizel M.B.A. Chief Commercial Officer 1979
Darren Opland Director of Corporate Communications NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 22, 2026 Ari Maizel N/A Sale 7.50K $182.42 $1.37M
Feb 26, 2026 Mark Coleman N/A Sale 25.00K $161.11 $4.03M
Feb 26, 2026 Mark L Jacobson N/A Sale 35.38K $161.88 $5.73M
Feb 02, 2026 Herriot Tabuteau N/A Sale 32.41K $185.60 $6.02M
Jan 22, 2026 Nick Pizzie N/A Sale 12.00K $187.92 $2.26M
Jan 21, 2026 Ari Maizel N/A Sale 7.50K $184.44 $1.38M
Jan 07, 2026 Herriot Tabuteau N/A Sale 31.26K $170.38 $5.33M
Jan 06, 2026 Herriot Tabuteau N/A Sale 29.45K $172.33 $5.08M
Jan 05, 2026 Herriot Tabuteau N/A Sale 78.70K $171.28 $13.48M
Dec 31, 2025 Mark E Saad N/A Sale 37.58K $165.18 $6.21M
Dec 04, 2025 Herriot Tabuteau N/A Sale 10.56K $148.18 $1.56M
Dec 03, 2025 Herriot Tabuteau N/A Sale 20.16K $146.94 $2.96M
Dec 02, 2025 Herriot Tabuteau N/A Sale 49.25K $144.59 $7.12M
Nov 05, 2025 Herriot Tabuteau N/A Sale 21.78K $134.49 $2.93M
Nov 04, 2025 Herriot Tabuteau N/A Sale 50.46K $133.79 $6.75M
Nov 03, 2025 Herriot Tabuteau N/A Sale 91.71K $132.34 $12.14M
Oct 08, 2025 Herriot Tabuteau N/A Sale 12.77K $118.84 $1.52M
Oct 07, 2025 Herriot Tabuteau N/A Sale 13.39K $118.77 $1.59M
Oct 06, 2025 Herriot Tabuteau N/A Sale 19.22K $120.17 $2.31M
Sep 22, 2025 Mark L Jacobson N/A Sale 10.00K $115.96 $1.16M

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 3.91M Mar 31, 2026 7.47% $0.01 -0.02%
Vanguard Portfolio Management, LLC 2.06M Mar 31, 2026 3.93% $0.02 0.00%
Vanguard Capital Management, LLC 1.94M Mar 31, 2026 3.70% $0.01 0.00%
FMR Inc 1.57M Mar 31, 2026 2.99% $0.01 32.61%
T. Rowe Price Associates, Inc. 1.32M Mar 31, 2026 2.51% $0.03 -12.77%
Amvescap Plc. 1.30M Mar 31, 2026 2.48% $0.02 1.90%
Geode Capital Management, LLC 1.16M Mar 31, 2026 2.22% $0.01 15.12%
State Street Corp 986.81K Mar 31, 2026 1.88% $0.01 2.99%
Delaware Management Holdings Inc 812.81K Mar 31, 2026 1.55% $0.24 -17.85%
Deep Track Capital, LP 700.00K Jun 30, 2026 1.34% $2.49 -36.36%
Wellington Management Company LLP 653.92K Jun 30, 2026 1.25% $0.03 -42.90%
Alethea Capital Management, LLC 649.11K Mar 31, 2026 1.24% $56.28 -2.93%
D. E. Shaw & Co LP 604.75K Jun 30, 2026 1.15% $0.07 0.21%
Bank of America Corp 598.09K Mar 31, 2026 1.14% $0.01 -3.23%
Millennium Management LLC 556.09K Jun 30, 2026 1.06% $0.05 2,578.91%
UBS Group AG 547.20K Mar 31, 2026 1.04% $0.01 54.00%
NORGES BANK 514.27K Jun 30, 2026 0.98% $0.01 3.80%
First Trust Advisors L.P. 482.06K Jun 30, 2026 0.92% $0.07 -16.52%
Morgan Stanley - Brokerage Accounts 476.70K Mar 31, 2026 0.91% $0.00 -2.95%
Assenagon Asset Management SA 454.68K Jun 30, 2026 0.87% $0.14 -47.49%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 1.39M 2.66% ▲ 0.32% Jul 31, 2026
2 Vanguard Small Cap Index 1.00M 1.92% ▲ 0.18% Jul 31, 2026
3 Vanguard MStar Small Cap Growth Indx Inv 581.83K 1.11% ▲ 0.44% Jul 31, 2026
4 Vanguard Explorer Inv 506.00K 0.97% ▲ 38.47% Jun 30, 2026
5 Vanguard Institutional Extnd Mkt Idx Tr 497.61K 0.95% ▲ 0.33% Jul 31, 2026
6 Invesco Discovery A 491.09K 0.94% ▲ 1.98% Jul 31, 2026
7 Invesco OFI Small Cap Growth 481.54K 0.92% ▼ 0.20% Jun 30, 2026
8 First Trust NYSE Arca Biotech ETF 387.24K 0.74% ▲ 0.00% Aug 31, 2026
9 iShares Biotechnology ETF 322.42K 0.62% ▲ 0.54% Aug 31, 2026
10 Franklin Innovation Composite 311.30K 0.59% ▲ 3.77% Jul 31, 2026

Financial Highlights

Market Cap: $11.56B
EBITDA: $-172.92M
PEG Ratio: $0.00
Book Value: $1.59
Earnings/Share: $-3.75
Profit Margin: -24.68%
Operating Margin: -23.42%
ROA (TTM): -16.31%
ROE (TTM): -245.10%
Revenue (TTM): $776.57M
Revenue/Share (TTM): $15.25
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 45.50%

Valuation Metrics

Enterprise Value: $10.96B
Trailing P/E: 0.00
Forward P/E: 35.09

Shares Statistics

Shares Outstanding: 52.38M
Shares Float: 44.46M
% Insiders: 15.08%
% Institutions: 74.62%
Short % Float: 9.12%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$638.50M
Cost of Goods Sold
adjust
$-47.48M
Gross Profit
subtotal
$591.02M
SG&A
adjust
$-570.60M
R&D
adjust
$-183.28M
Other Operating Expense
adjust
$-6.38M
Operating Income
subtotal
$-169.24M
Other / Non-Operating Items
adjust
$-13.94M
Net Income
subtotal
$-183.17M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about AXSM.US!